• Aqsa Mazhar, Afza Naureen, Yousuf Abd Mallick, and Lubna Samad.
• Aqsa Mazhar, MBBS, FCPS Vascular Anomalies Center, The Indus Hospital And Health Network, Karachi, Pakistan.
• Pak J Med Sci. 2024 Jan 1; 40 (2ICON Suppl): S75S79S75-S79.

ObjectiveThis study aimed to evaluate the efficacy and safety of 0.5% timolol maleate gel, reported as an efficacious option for management of infantile hemangiomas (IH) in children.MethodsA retrospective study was conducted among patients diagnosed with IH from January 2019 to December 2021. All patients were treated 0.5% timolol gel. Data parameters, including photographs, at baseline and the final or most recent follow-up visit, were reviewed. Outcomes based on photographic assessment were categorized as excellent, good, fair or poor.ResultsSixty-four children with 76 lesions were enrolled. Median age was eight months (two months to 36 months) with most lesions (75.0%) presenting during the first year of life. Female preponderance (84.4%) was seen and the cervicofacial region was most commonly involved (52.6%). The majority of lesions (54, 84.4%) were solitary and most were treatment naïve (n=61, 80.3%). Excellent, good, fair, and poor responses were seen in 24 (31.5%), 39 (51.3%), 6 (7.9%), and 7 (9.2%) lesions. No complications were seen and no statistically significant difference was observed with respect to gender, age group, region involved and treatment naïve versus previously treated patients.ConclusionTimolol maleate 0.5% gel is an effective and safe treatment option for IH irrespective of location of lesion, age and history of prior treatment.Copyright: © Pakistan Journal of Medical Sciences.

3 keywords...

hide…